Steve Pakola, M.D. is the Chief Medical Officer for REGENXBIO. Prior to joining REGENXBIO, Dr. Pakola was Chief Medical Officer at Aerpio Pharmaceuticals. Dr. Pakola brings more than 20 years of biopharmaceutical experience, including holding key leadership roles in preclinical and clinical development, regulatory affairs and medical affairs. Dr. Pakola’s therapeutic area experience encompasses retinal disorders, including diabetic retinopathy, diabetic macular edema and age-related macular degeneration, as well as other non-ophthalmic disease areas. He was the lead inventor and program lead for the Jetrea® (ocriplasmin) program, from inception in 2002 through the therapy’s United States and European regulatory submissions in 2012.
Prior to Aerpio, Dr. Pakola served as Chief Medical Officer at Amakem NV and ThromboGenics Inc. Earlier in his career, Dr. Pakola served as Associate Director of Cardiovascular Clinical Research at Boehringer Ingelheim, where he was Global Medical Lead on the Lipid-Lowering Development Program and the USA Medical Lead for the Direct Thrombin Inhibitor Dabigatran Program. Prior to that, Dr. Pakola served in senior-level clinical development positions at Quintiles Cardiovascular Therapeutics and at Organon.
Dr. Pakola earned a B.A., summa cum laude, and an M.D. from the University of Pennsylvania, where he was elected to the Alpha Omega Alpha Honor Medical Society.
What is Steve Pakola's net worth?
The estimated net worth of Steve Pakola is at least $1.73 million as of March 5th, 2024. Mr. Pakola owns 107,192 shares of REGENXBIO stock worth more than $1,726,863 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Pakola may own. Learn More about Steve Pakola's net worth.
How do I contact Steve Pakola?
Has Steve Pakola been buying or selling shares of REGENXBIO?
Steve Pakola has not been actively trading shares of REGENXBIO during the last ninety days. Most recently, Steve Pakola sold 12,878 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $28.36, for a transaction totalling $365,220.08. Following the completion of the sale, the insider now directly owns 107,192 shares of the company's stock, valued at $3,039,965.12. Learn More on Steve Pakola's trading history.
Who are REGENXBIO's active insiders?
Are insiders buying or selling shares of REGENXBIO?
In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 165,115 shares worth more than $3,085,821.51. The most recent insider tranaction occured on April, 15th when CEO Kenneth T Mills sold 15,000 shares worth more than $272,850.00. Insiders at REGENXBIO own 13.1% of the company.
Learn More about insider trades at REGENXBIO. Information on this page was last updated on 4/15/2024.
